Last reviewed · How we verify
TCD601
At a glance
| Generic name | TCD601 |
|---|---|
| Also known as | Siplizumab, siplizumab |
| Sponsor | ITB-Med LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (PHASE1)
- A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation (PHASE2)
- Siplizumab for Sickle Cell Disease Transplant (PHASE1, PHASE2)
- Siplizumab in T1DM (PHASE1, PHASE2)
- A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE) (PHASE2)
- A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA) (PHASE2)
- A Study of TCD601 in de Novo Renal Transplant Recipients (PHASE2)
- A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TCD601 CI brief — competitive landscape report
- TCD601 updates RSS · CI watch RSS
- ITB-Med LLC portfolio CI